Yahoo
NasdaqGS - Delayed Quote USD

Outset Medical, Inc. (OM)

3.5650 -0.1050 (-2.86%)
At close: September 3 at 4:00:00 PM EDT
3.7400 +0.1750 (+4.91%)
Pre-Market: 7:00:00 AM EDT
Chart Range Bar
Loading chart for OM
  • Previous Close 3.6700
  • Open 3.7000
  • Bid 2.6000 x 100
  • Ask 4.5500 x 100
  • Day's Range 3.5400 - 3.7416
  • 52 Week Range 3.0000 - 16.1600
  • Volume 91,774
  • Avg. Volume 194,620
  • Market Cap (intraday) 67.012M
  • Beta (5Y Monthly) 1.90
  • PE Ratio (TTM) --
  • EPS (TTM) -3.6900
  • Earnings Date (est.) Nov 9, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.67

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

www.outsetmedical.com

310

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OM
3.91%
S&P 500 (^GSPC)
13.18%

1-Year Return

OM
74.11%
S&P 500 (^GSPC)
20.15%

3-Year Return

OM
98.29%
S&P 500 (^GSPC)
71.57%

5-Year Return

OM
99.52%
S&P 500 (^GSPC)
70.83%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 31.64M
Earnings -17.98M
Profit Margin -56.85%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
0
10M
20M
30M
-68.0%
-66.0%
-64.0%
-62.0%
-60.0%
-58.0%

Analyst Insights

View More

Analyst Price Targets

6.00
7.67 Average
3.5650 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 2/12/2026
Analyst BTIG
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 17 -> 15

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    68.42M

  • Enterprise Value

    25.68M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.56

  • Price/Book (mrq)

    0.71

  • Enterprise Value/Revenue

    0.22

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -63.06%

  • Return on Assets (ttm)

    -15.54%

  • Return on Equity (ttm)

    -59.17%

  • Revenue (ttm)

    117.8M

  • Net Income Avi to Common (ttm)

    -74.29M

  • Diluted EPS (ttm)

    -3.6900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    147.19M

  • Total Debt/Equity (mrq)

    108.42%

  • Levered Free Cash Flow (ttm)

    -14.68M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.5650 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: